Marcoto et al. found that the levels of TAP1 and CD80 decreased in breast cancer stem cells after decitabine treatment, thereby reducing the recognition and killing effect of T cells and promoting tumor cell growth (Sultan et al., 2018). Here, CD80 is linked to breast cancer.